“Biotech Wildcatting” -- How One Company Attempts to Mitigate Drug Development Risk and Create Smart Medicines
Developing innovative biopharmaceutical products has more business risk than energy exploration or “wildcatting”. At Arisaph, they understand that drug development is replete with risk and they adopt strategies to mitigate their business risk to increase chances at ultimate success, which is not guaranteed by any means.
Chris Kiritsy, Co-Founder and CEO of Arisaph Pharmaceuticals will describe how certain strategies contributed to the success of their prior enterprise, Kos Pharmaceuticals, Inc., and how they are utilizing additional strategies in building Arisaph, which has more far-reaching and innovative technology.
Find out what's happening in Walthamfor free with the latest updates from Patch.
In their pursuit to Create Smart Medicines, Arisaph is applying the understandings of both chemistry and biology to develop transformational therapies for cancer, diabetes and cardiovascular disease. Chris will speak about these challenges and how they affect us all!
